Travere therapeutics announces fda accelerated approval of filspari™ (sparsentan), the first and only non-immunosuppressive therapy for the reduction of proteinuria in iga nephropathy

First single molecule dual endothelin angiotensin receptor antagonist (deara) approved for use in patients withiga nephropathy (igan)
TVTX Ratings Summary
TVTX Quant Ranking